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ABSTRACT
The goal of my project as outlined in the original application is to analyze the role of Protein Kinase D (PKD) in breast cancer cell motility, the phenotype critical for metastasis. The work I have conducted includes the demonstration that loss of PKD in a number of highly metastatic breast cancer cell lines results in a migration defect. I have also discovered a potential isoform specificity of PKD in the control of breast cancer cell motility.
Introduction
The goal of my project as outlined in the original application is to analyze the role of Protein Kinase D (PKD) isoforms in breast cancer cell motility, the phenotype critical for metastasis. PKD is a serine/threonine kinase that has been best characterized as a key regulator of vesicular fission in golgi trafficking (1), a process is necessary for the delivery and secretion of molecules destined for the plasma membrane. This highlights its importance in homeostatic cell signaling, but despite four independent studies (2), (3), (4), (5) identifying upregulation and mutations of PKD in cancer tissue, a potential role for PKD in cancer progression has not been well explored. Based in part on a recent study which links PKD to fibroblast cell migration (6) , I hypothesized that a PKD signaling network controls cytoskeletal reorganization and cellular adhesion, thereby regulating cell motility. I have tested the invasive migration of PKD1, PKD2, and PKD3-knockdown cells in transwell motility assays using 3T3-conditioned media as chemoattractant. I am exploring the specific mechanisms and signaling effectors that control this phenotype using mutant PKD constructs refractory to silencing by shRNA and a panel of both known and putative PKD substrates, mutated at known/putative sites of modification by. I have generating preliminary data which may result in the finding of a novel substrate of PKD. I will use live cell microscopy and immunofluorescence as additional methods to better elucidate the mechanism by which PKD controls invasive migration. This work will determine the regulation and function of a previously uncharacterized signaling pathway that is critical for breast cancer progression, the PKD signaling axis, and how it impacts invasive migration. The results of this research will yield an increased understanding of mechanisms that control the metastatic phenotype of breast carcinoma cells, subsequently allowing for new therapeutic strategies targeted to advanced stage tumors.
Body
The To characterize the specific cytoskeletal changes that occur as a result of PKD loss using live cell microscopy (months 29-36).
a. Conduct time-lapse microscopy to compare efficiency of control and PKD-knockdown breast cancer cells to migrate (months 29-32).
b. Determine subcellular localization of PKD in breast cancer cell lines using GFP visualization and immunofluorescence (months 32-34).
c. Analyze specific cytoskeletal differences between control and PKD-knockdown migrating cells using time-lapse microscopy and immunofluorescent staining for cytoskeletal markers (months 34-36).
Progress
To investigate PKD isoform-specific mechanisms and substrates that control invasive migration in To investigate the role of PKD isoforms and specific PKD sites and domains, I am conducting migration defect rescue experiments. As reported previously, I generated mutant alleles of both PKD1
and PKD2 that are refractory to silencing by shRNA and contain mutations in domains of interest and phosphorylation sites. I developed a technique of depleting endogenous PKD and introducing mutant PKD alleles which involves the use of both lentiviral and retroviral infection. I introduced either vector or the PKD non-silenceable rescue alleles retrovirally and selected a pool of positive infectants. This is followed by efficient knockdown of PKD isoforms using lentivirally delivered shRNAs that I have previously characterized. This method, compared to the more standard knockdown followed by transient transfection of PKD alleles, ensures viability of PKD-knockdown cells as well as efficient over-expression of re-introduced PKD alleles. Although I was able to achieve both PKD knockdown and over-expression of rescue constructs, I did not observe rescue of the migration defect caused by PKD knockdown (FIGURE 4 ). There are a few potential explanations for this result. PKD knockdown could cause irrevocable damage to the signaling networks and/or cellular mechanisms that control migration. Also, the differences between endogenous and re-introduced PKD could be responsible. Specifically, the tag on the rescue alleles could interfere with PKD function in this context. Also, the rescue alleles do not contain the untranslated regions of the gene that could be required for proper localization of PKD towards cell migration. To determine whether these latter scenarios could be the cause of the discrepancy, I obtained a full-length, untagged allele of PKD that I cloned into a mammalian expression vector. I am currently conducting experiments using this construct to determine whether it rescues the migration defect of breast cancer cells. If I am able to achieve rescue using this PKD construct, I will generate mutations in domains and phosphorylation sites of interest to determine their contribution towards cell migration. To characterize the specific cytoskeletal changes that occur as a result of PKD loss using live cell microscopy My focus on the above and further investigation of exciting and unexpected results has prevented me from performing these experiments. I intend to complete them within the next 6 months to be included in the manuscript I am developing. 
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Current research and future directions
As a result of the discovery that PKD controls cell migration in an isoform-specific manner, I
have sought to develop a high-impact study demonstrating a role for PKD isoforms in the control of breast cancer cell migration and delineating the specific mechanisms by which PKD isoforms and their signaling substrates that control this phenotype. I intend for the manuscript I am developing to encompass a comprehensive study demonstrating first the migration-defect phenotype I observe for PKD-knockdown cells and then describing the specific signaling mechanisms by which PKD isoforms control this phenotype. This section will optimally include PKD mutant allele rescue analysis to determine which PKD domains and phosphorylation sites are responsible for this phenotype.
Therefore, a primary ongoing effort is to repeat the rescue experiments using a full-length, un-tagged PKD that is refractory to silencing by shRNA. I would also like this section to highlight the role(s) of PKD substrates and effectors that control cell migrations. I therefore am testing the possibility that PKD signals through Rabaptin-5 to control cell migration. I am analyzing the phosphorylation of Rabaptin-5 (using the PKD-substrate-directed antibody) in cells in which PKD is present or depleted and in which PKD is stimulated or overepressed. I am also generating both non-phosphorylatable and phospho-mimetic alleles of Rabaptin-5 to determine the functional relevance of PKD-phosphorylation at this site. Whether Rabaptin-5 mediates signals by which PKD controls cell migration or not, the discovery that it is a PKD substrate would be a novel and important finding worthy of further investigation. And finally, I would like to include live cell microscopy and immuno-fluorescence analyses to determine both the localization of PKD and the specific morphological defects that account for the impaired migration phenotype.
Key Research Accomplishments and Reportable Outcomes
• Completed a comprehensive analysis of the control of PKD isoforms towards cellular migration in two breast cancer cell lines, including the relatively uncharacterized PKD3 isoform.
• Successfully achieved PKD knockdown/over-expression experiments although, unexpectedly, rescue of the migration defect caused by PKD knockdown was not observed.
• Discovered a putative substrate of PKD, Rabaptin-5, which would represent the first link between PKD and the control of endocytosis, and which could be mediating PKD-controlled invasive migration.
Conclusion
The overarching goal of my project as outlined in the original application has been to analyze the role of Protein Kinase D (PKD) isoforms in breast cancer cell motility, the phenotype critical for metastasis.
In my first year of study I optimized both overexpression and silencing cell infection systems with which to conduct gain and loss of function experiments using breast cancer cell lines in invasive migration transwell assays. I also worked in collaboration with CRT to develop and test a panel of PKD-specific inhibitors. I was thereby able to determine a reproducible migration-defect phenotype of PKD-knockdown and inhibition in HS578T cells, which are a highly metastatic breast cancer cell line.
I also observed a loss on cellular viability caused by PKD depletion which, by means of thorough Propidium Iodide-FACS analysis I found to be an artifact caused by use of a first generation PKD inhibitor. This allows me to conclude that the migration-defect phenotype I observe of PKDknockdown cells is not due to a general viability issue but instead due to the impairment of the specific signaling networks controlled by PKD.
In the following year of study, I demonstrated that PKD loss by lentiviral shRNA knockdown results in a migration defect phenotype in a number of metastatic breast and prostate cancer cell lines. I further demonstrated that the PKD2 signaling network is dominant in the control of this phenotype in breast cancer cell types Sum159PT and BT549. I confirmed by RT-PCR that both isoforms are present in significant quantities in at least one of these cell types and therefore discovered a potential isoform specificity of PKD in the control of breast cancer cell motility. As a result of this discovery, I decided to broaden the scope of my studies to focus on isoform specific mechanisms and a number of potential substrates that control this phenotype. I therefore created a number of PKD1 and 2 non-silenceable and PKD substrate mutant alleles for PKD-knockdown/rescue analysis.
In my final year of study I sought to gain insights about the signaling and mechanisms of PKD-controlled breast cancer cell migration using these mutant alleles in the transwell migration assay. I developed an efficient PKD knockdown/ over-expression system for use in the transwell migration assays but unexpectedly did not observe rescue of the migration defect caused by PKD knockdown. This is likely either due to irrevocable damage to the migration machinery caused by PKD or because of the differences between endogenous and re-introduced To summarize, I have demonstrated that PKD2 and PKD3 isoforms are required for cell migration in breast cancer cell lines while, unexpectedly, PKD1, the best-characterized isoform, is not.
I developed both a panel of mutant PKD alleles for use and an efficient PKD knockdown/ overexpression system to gain better insights into the signaling mechanisms by which PKD isoforms control cell migration. Either because PKD knockdown causes irrevocable damage to the migration machinery or because of the differences between endogenous and re-introduced PKD I did not observe rescue of the migration defect caused by PKD knockdown. Furthermore, I have provided preliminary evidence that Rabaptin-5, a Rab-5 effector in endocytosis, is a substrate of PKD. These findings are novel and provide exciting possibilities for signaling mechanisms by which PKD controls breast cancer cell migration.
